New Jersey Senate Bill S3060

New Jersey 2024-2025 Regular Session

• Introduced: 4/8/24
• Refer: 4/8/24

Caption

Expands requirements for health insurance carriers concerning prostate cancer screening and requires coverage be provided without cost sharing.

Impact

If enacted, S3060 will alter the existing provisions of New Jersey law on health insurance coverage by extending mandatory prostate cancer screening benefits to a broader age range compared to previous regulations. Currently, only men aged 50 and over or those aged 40 and over with a familial predisposition to prostate cancer are guaranteed coverage. The bill aims to improve preventive healthcare access and to encourage early detection of prostate cancer, which can significantly affect the treatment outcomes and survival rates.

Summary

Senate Bill S3060, introduced in New Jersey, aims to enhance health insurance coverage for prostate cancer screenings. This legislation mandates that health insurance carriers cover annual prostate cancer screenings without imposing any cost-sharing requirements for men aged 40 to 75. The bill expands the definition of prostate cancer screening, which now includes digital rectal exams, prostate-specific antigen tests, and any medically recognized follow-up tests such as urinary analysis and imaging studies.

Contention

While S3060 has the potential to increase health equity by reducing barriers to necessary screenings, there may be concerns regarding the financial implications for health insurance providers. Opponents might argue that the removal of cost-sharing could lead to increased premiums for all policyholders as insurers adjust to the expanded coverage. Supporters, however, emphasize the bill's role in promoting men's health and future savings by potentially decreasing the need for more extensive treatments resulting from late-stage cancer diagnoses.